Ignite Proteomics offers the only commercially available and clinically validated assay that measures both the expression and activation levels of drug targets in breast tumors. This innovative ...

Credit: Thinkstock Investigators explored the potential of a noninvasive ctDNA assay as a predictive biomarker for advanced or metastatic urothelial cancer ... of total cell-free DNA (cfDNA ...

This metabolic shift is central to cancer cell aggression and survival. The current work delves ... and various cellular assays. The results revealed that ING5 overexpression significantly ...

Detailed price information for Predictive Oncology Inc (POAI-Q) from The Globe and Mail including charting and trades.